Why the study?
Are heart valve implantations cost-effective compared to standard treatment or alternative surgical options in patients with severe aortic stenosis or mitral valve disease?
Are heart valve implantations cost-effective compared to standard treatment or alternative surgical options in patients with severe aortic stenosis or mitral valve disease?
TAVI is generally cost-effective compared to standard treatment in inoperable or high-risk patients, and SAVR is cost-effective compared to standard treatment in operable patients, though the cost-effectiveness of TAVI versus SAVR in high-risk patients remains inconsistent.
Supports TAVI in inoperable/high-risk and SAVR in operable aortic stenosis patients; confirms cost-effectiveness versus standard care across economic evaluations.
OBJECTIVE: To review the evidence on the cost-effectiveness of heart valve implantations generated by decision analytic models and to assess their methodological quality. METHODS: A systematic review was performed including model-based cost-effectiveness analyses of heart valve implantations. Study and model characteristics and cost-effectiveness results were extracted and the methodological quality was assessed using the Philips checklist. RESULTS: Fourteen decision-analytic models regarding the cost-effectiveness of heart valve implantations were identified. In most studies transcatheter aortic valve implantation (TAVI) was cost-effective compared to standard treatment (ST) in inoperable or high-risk operable patients (ICER range 18,421-120,779 €) and in all studies surgical aortic valve replacement (SAVR) was cost-effective compared to ST in operable patients (ICER range 14,108-40,944 €), but the results were not consistent on the cost-effectiveness of TAVI versus SAVR in high-risk operable patients (ICER range: dominant to dominated by SAVR). Mechanical mitral valve replacement (MVR) had the lowest costs per success compared to mitral valve repair and biological MVR. The methodological quality of the studies was moderate to good. CONCLUSION: This review showed that improvements can be made in the description and justification of methods and data sources, sensitivity analysis on extrapolation of results, subgroup analyses, consideration of methodological and structural uncertainty, and consistency (i.e. validity) of the models. There are several opportunities for future decision-analytic models of the cost-effectiveness of heart valve implantations: considering heart valve implantations in other valve positions besides the aortic valve, using a societal perspective, and developing patient-simulation models to investigate the impact of patient characteristics on outcomes.
No takes yet. Share an insight, caveat, or question.
Huygens et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: